X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-08 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $93.82 | -5,000 | 47,181 | -10% | -$469,077 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.36 | -11,131 | 440,003 | -2% | -$59,646 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.38 | -49,338 | 518,437 | -9% | -$265,242 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.36 | -9,620 | 303,451 | -3% | -$51,549 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.36 | -56,344 | 1,374,079 | -4% | -$301,921 | |||||
| D | 2026-06-05 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $80.00 | -3,312 | 180,393 | -2% | -$264,960 | |||||
| D | 2026-06-08 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $547.51 | -10,000 | 18,876 | -35% | -$5,475,045 | |||||
2026-06-05 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | S - Sale | $19.41 | -10,500 | 43,415 | -19% | -$203,820 | ||||||
2026-06-05 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $19.45 | +10,500 | 43,415 | +32% | +$204,260 | ||||||
| D | 2026-06-09 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $67.98 | -3,500 | 153,902 | -2% | -$237,930 | |||||
2026-06-08 | TNXP | Tonix Pharmaceuticals Holding Corp. | Stillwell Richard Newcomb | Dir | P - Purchase | $11.65 | +5,000 | 5,000 | New | +$58,250 | ||||||
2026-06-09 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $11.79 | +5,000 | 29,007 | +21% | +$58,950 | ||||||
| D | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $241.01 | -49,670 | 7,351,729 | -1% | -$11,970,967 | |||||
| D | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | S - Sale+OE | $240.09 | -33,000 | 43,355 | -43% | -$7,922,970 | |||||
| D | 2026-06-08 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $16.94 | +2,000 | 24,500 | +9% | +$33,880 | |||||
2026-06-05 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $34.54 | -10,000 | 51,884 | -16% | -$345,351 | ||||||
| D | 2026-06-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.49 | -9,500 | 668,728 | -1% | -$5,201,110 | |||||
2026-06-05 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,745 | 21,015 | -8% | -$785,250 | ||||||
| D | 2026-06-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $27.30 | -5,222 | 139,763 | -4% | -$142,561 | |||||
2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Patou Gary | Dir | S - Sale | $53.14 | -1,322 | 29,798 | -4% | -$70,251 | ||||||
2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Cannon Gillian | Dir | S - Sale | $53.14 | -1,190 | 1,455 | -45% | -$63,237 | ||||||
2026-06-04 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale | $16.27 | -169,427 | 109,850 | -61% | -$2,756,984 | ||||||
| D | 2026-06-08 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale+OE | $15.44 | -23,214 | 67,894 | -25% | -$358,452 | |||||
| D | 2026-02-13 | CING | Cingulate Inc. | Hargroves Thomas Jeffrey | Dir | P - Purchase | $5.04 | +97,276 | 97,468 | >999% | +$490,271 | |||||
2026-06-04 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.08 | +843,622 | 0 | -100% | +$64,115 | ||||||
2026-06-05 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $0.06 | -735,462 | 0 | -100% | -$45,599 | ||||||
| M | 2026-06-04 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.41 | -105,565 | 377,211 | -22% | -$43,029 | |||||
| M | 2026-06-04 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $67.67 | -80,000 | 5,077,460 | -2% | -$5,413,289 | |||||
2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Dir | S - Sale | $63.91 | -200,000 | 5,033,799 | -4% | -$12,782,059 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Dir | S - Sale | $10.73 | -2,625 | 9,767 | -21% | -$28,166 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Dir | S - Sale | $10.73 | -2,625 | 263,238 | -1% | -$28,166 | ||||||
| D | 2026-06-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.63 | -9,500 | 668,728 | -1% | -$5,202,436 | |||||
| M | 2026-06-04 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $64.95 | -84,800 | 1,850,954 | -4% | -$5,507,782 | |||||
| DM | 2026-06-04 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.25 | -34,976 | 700,000 | -5% | -$218,561 | |||||
| D | 2026-06-05 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $34.35 | -6,153 | 1,177,529 | -1% | -$211,356 | |||||
2026-06-04 | PHVS | Pharvaris N.V. | Nijdam Anna | Principal Accounting Officer | S - Sale | $30.87 | -2,670 | 46,275 | -5% | -$82,425 | ||||||
| D | 2026-06-03 | XERS | Xeris Biopharma Holdings, Inc. | Persky Marla | Dir | S - Sale+OE | $5.90 | -15,500 | 157,063 | -9% | -$91,433 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Halkuff Dawn | Dir | S - Sale+OE | $6.09 | -20,000 | 124,603 | -14% | -$121,886 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Bormann-Kennedy Barbara-Jean Anne | Dir | S - Sale+OE | $6.09 | -16,000 | 150,693 | -10% | -$97,507 | |||||
| D | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale+OE | $6.09 | -15,000 | 707,276 | -2% | -$91,422 | |||||
2026-06-04 | PCRX | Pacira Biosciences, Inc. | Williams Kristen | Chief Administrative Officer | S - Sale | $22.27 | -10,259 | 167,062 | -6% | -$228,468 | ||||||
| M | 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $4.37 | -8,285 | 373,224 | -2% | -$36,209 | |||||
| D | 2026-06-03 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $30.01 | -2,645 | 20,439 | -11% | -$79,376 | |||||
| D | 2026-06-05 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.93 | -14,584 | 62,586 | -19% | -$42,737 | |||||
| M | 2026-06-04 | EQ | Equillium, Inc. | Connelly Stephen | Pres, CSO | S - Sale | $3.13 | -230,975 | 762,025 | -23% | -$723,830 | |||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $546.28 | -10,000 | 18,876 | -35% | -$5,462,824 | |||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $546.33 | -9,500 | 668,728 | -1% | -$5,190,128 | |||||
2026-06-03 | ALDX | Aldeyra Therapeutics, Inc. | Brady Todd C | Pres, CEO | P - Purchase | $1.67 | +250,000 | 1,721,298 | +17% | +$418,450 | ||||||
2026-06-03 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $102.27 | -2,370 | 98,603 | -2% | -$242,380 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Seth Alpna | Dir | S - Sale | $10.72 | -2,625 | 9,767 | -21% | -$28,140 | ||||||
2026-06-03 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $102.27 | -2,404 | 69,082 | -3% | -$245,857 | ||||||
2026-06-03 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $102.27 | -2,159 | 39,454 | -5% | -$220,801 | ||||||
2026-06-03 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $102.27 | -7,605 | 499,356 | -2% | -$777,763 | ||||||
| M | 2026-06-03 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $102.90 | -4,424 | 60,486 | -7% | -$455,248 | |||||
2026-06-03 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $17.48 | +2,500 | 22,500 | +13% | +$43,700 | ||||||
2026-06-03 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $8.55 | -10,000 | 74,821 | -12% | -$85,459 | ||||||
2026-06-03 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $8.27 | -14,828 | 300,079 | -5% | -$122,628 | ||||||
2026-06-04 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.31 | +50,000 | 1,068,000 | +5% | +$465,295 | ||||||
2026-06-03 | GNLX | Genelux Corp | Smalling Ralph | Head of Regulatory | S - Sale | $2.93 | -192 | 67,611 | 0% | -$563 | ||||||
2026-06-02 | JANX | Janux Therapeutics, Inc. | Doyle Janeen Noel | Chief Corp., Bus. Dev. Ofcr | S - Sale | $14.03 | -4,059 | 75,941 | -5% | -$56,944 | ||||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $14.60 | +100,000 | 606,205,809 | 0% | +$1,460,000 | ||||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $14.60 | +100,000 | 606,205,809 | 0% | +$1,460,000 | ||||||
| D | 2026-06-04 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $547.07 | -8,300 | 45,172 | -16% | -$4,540,642 | |||||
2026-06-04 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $43.05 | -2,034 | 229,524 | -1% | -$87,564 | ||||||
| D | 2026-06-02 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $70.60 | -20,000 | 3,985 | -83% | -$1,412,000 | |||||
2026-06-04 | SMMT | Summit Therapeutics Inc. | Soni Manmeet Singh | COO, CFO | P - Purchase | $14.45 | +50,000 | 3,123,603 | +2% | +$722,250 | ||||||
| D | 2026-06-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.61 | -9,500 | 668,728 | -1% | -$5,202,271 | |||||
| D | 2026-06-03 | TEVA | Teva Pharmaceutical Industries Ltd | Shields Matthew | EVP, Global Operations | S - Sale+OE | $32.87 | -16,195 | 9,989 | -62% | -$532,330 | |||||
| D | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $75.00 | -8,333 | 0 | -100% | -$624,975 | |||||
2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $70.43 | -15,000 | 597,540 | -2% | -$1,056,486 | ||||||
| D | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $71.06 | -7,500 | 97,994 | -7% | -$532,937 | |||||
| D | 2026-06-02 | EVMN | Evommune, Inc. | Cohen David E | Dir | S - Sale+OE | $20.33 | -6,056 | 17,609 | -26% | -$123,094 | |||||
| D | 2026-06-01 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Chief Scientific Officer | S - Sale+OE | $22.74 | -16,687 | 46,403 | -26% | -$379,462 | |||||
2026-06-01 | EVMN | Evommune, Inc. | Pena Luis C. | Pres, CEO | S - Sale | $22.74 | -16,787 | 637,896 | -3% | -$381,736 | ||||||
| D | 2026-06-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $70.21 | -25,000 | 119,472 | -17% | -$1,755,183 | |||||
| D | 2026-06-01 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $70.00 | -40,000 | 16,130 | -71% | -$2,800,004 | |||||
| D | 2026-06-01 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $28.93 | -5,935 | 793 | -88% | -$171,682 | |||||
2026-06-01 | NATR | Natures Sunshine Products Inc | Norman Daniel C | EVP, Pres, Asia | S - Sale | $20.64 | -9,713 | 47,276 | -17% | -$200,476 | ||||||
| M | 2026-06-01 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.46 | -139,803 | 482,776 | -22% | -$63,628 | |||||
| D | 2026-06-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $22.87 | -27,000 | 115,743 | -19% | -$617,571 | |||||
| M | 2026-06-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Chief Business Officer | P - Purchase | $7.50 | +13,500 | 75,300 | +22% | +$101,219 | |||||
| D | 2026-06-01 | IONS | Ionis Pharmaceuticals Inc | Berthelsen Spencer R | Dir | S - Sale+OE | $75.67 | -8,000 | 156,083 | -5% | -$605,360 | |||||
2026-06-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $30.58 | -1,795 | 34,826 | -5% | -$54,891 | ||||||
2026-06-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $235.12 | -6,000 | 372,682 | -2% | -$1,410,720 | ||||||
| D | 2026-06-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.39 | -9,500 | 668,728 | -1% | -$5,114,742 | |||||
2026-06-01 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $60.87 | -276 | 146,743 | 0% | -$16,800 | ||||||
| M | 2026-06-01 | LQDA | Liquidia Corp | Kirsch Arthur S | Dir | S - Sale | $57.71 | -30,000 | 40,755 | -42% | -$1,731,300 | |||||
| D | 2026-06-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $98.69 | -11,430 | 85,533 | -12% | -$1,128,080 | |||||
| D | 2026-06-01 | ALNY | Alnylam Pharmaceuticals, Inc. | Pyott David E I | Dir | S - Sale+OE | $299.18 | -3,830 | 29,482 | -11% | -$1,145,853 | |||||
2026-06-01 | ONC | Beone Medicines Ltd. | Yi Qingqing | Dir | S - Sale | $279.13 | -235 | 24,271 | -1% | -$65,596 | ||||||
2026-06-01 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $439.91 | -828 | 19,959 | -4% | -$364,245 | ||||||
2026-06-02 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.43 | +50,000 | 1,018,000 | +5% | +$471,300 | ||||||
2026-06-01 | SPRC | Scisparc Ltd. | Shrem Itschak | Dir | S - Sale | $10.00 | -462 | 10,596 | -4% | -$4,620 | ||||||
| DM | 2026-05-29 | AUPH | Aurinia Pharmaceuticals Inc. | Tang Kevin | CEO, 10% | P - Purchase | $15.29 | +814,606 | 13,044,106 | +7% | +$12,455,227 | |||||
2026-06-01 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $2.98 | -10,000 | 472,784 | -2% | -$29,801 | ||||||
| M | 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $4.72 | -652 | 381,509 | 0% | -$3,075 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $95.84 | -30,000 | 381,809 | -7% | -$2,875,103 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $100.00 | -3,977 | 0 | -100% | -$397,700 | |||||
| D | 2026-06-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $16.60 | -8,148 | 13,579 | -38% | -$135,253 | |||||
| D | 2026-06-01 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $90.62 | -26,530 | 4,000 | -87% | -$2,404,077 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |